Inspire Medical Systems, Inc.
$1.60B- Market cap
- $1.80B
- Debt
- +$112.36M
- Cash
- −$308.27M
Capital structure 94% equity / 6% debt · EV / Revenue 1.76x · EV / EBITDA 24.31x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: INSP stock price at premium vs CNXC $62.14 current versus $5.54 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at CNXC's multiple
Implied fair value · at INSP's multiple
Snapshot Sep 8, 2026, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: INSP FY 2025 (ended Dec 31, 2025) · CNXC FY 2025 (ended Nov 30, 2025). Fiscal years are not aligned.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
Market cap plus debt, less cash.
Capital structure 94% equity / 6% debt · EV / Revenue 1.76x · EV / EBITDA 24.31x
Capital structure 27% equity / 73% debt · EV / Revenue 0.61x
CNXC carries the larger enterprise value at $6.04B against $1.60B; CNXC trades on the lower EV / Revenue multiple (0.61x vs 1.76x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Inspire Medical Systems, Inc. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
CONCENTRIX CORPORATION · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.14x
1.69x
Net debt / EBITDA
Leverage against operating earnings
-2.98x
-21.70x
Cash and equivalents
Liquid reserves on the balance sheet
$308.27M
$327.35M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
$112.36M
$4.64B
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.